ClinConnect ClinConnect Logo
Search / Trial NCT05350332

Effects of Lung Volume on Upper Airway Patency During Drug Induced Sleep Endoscopy

Launched by EMORY UNIVERSITY · Apr 22, 2022

Trial Information

Current as of November 04, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how the amount of air in the lungs affects the throat's ability to stay open during sleep, especially for people with obstructive sleep apnea (OSA). OSA is a condition where a person's breathing repeatedly stops and starts during sleep, often causing choking sensations. To better understand how lung volume impacts throat collapse, participants will undergo a procedure called drug-induced sleep endoscopy (DISE), which allows doctors to see the throat while the patient is lightly sedated. Participants will be divided into two groups: one will use a special ventilator to change lung volumes, and the other will receive gentle electrical stimulation to help the diaphragm work better.

To be eligible for this study, you need to be at least 18 years old, have a diagnosis of OSA, and be interested in surgical options for treatment. You also need to be able to give consent and have no major health issues that could affect surgery or anesthesia. During the study, you can expect to have the DISE procedure as part of your regular evaluation, along with lung function tests. This research aims to improve how doctors assess patients for surgery and could lead to new treatment options for those with OSA.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult patients (≥ 18 yrs) willing and capable of providing informed consent
  • Obstructive sleep apnea (AHI ≥ 5 events/hour)
  • Must be willing and able to provide informed consent to participate in the study.
  • Interested in surgical treatments of OSA and have consented for a DISE procedure as part of their routine clinical evaluation.
  • Patients are evaluated and cleared by anesthesia prior to the procedure.
  • Exclusion Criteria:
  • No significant uncontrolled medical co-morbidities (e.g., uncontrolled hypertension, unstable angina, uncompensated heart failure or COPD).
  • Any medical comorbidity that would prevent the patient from receiving anesthesia or having surgery
  • Inability to tolerate negative pressure ventilator or perform PFT (i.e. claustrophobia)
  • No incapacitating disability that interferes with execution of the protocol

About Emory University

Emory University, a leading research institution located in Atlanta, Georgia, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, Emory harnesses the expertise of its renowned faculty and state-of-the-art facilities to conduct cutting-edge research across various fields, including oncology, neurology, and infectious diseases. The university's commitment to ethical research practices and patient safety ensures that all clinical trials are designed to generate valuable data that can lead to significant therapeutic advancements. By fostering partnerships with local hospitals and community organizations, Emory strives to translate research findings into real-world applications, ultimately enhancing health outcomes for diverse populations.

Locations

Atlanta, Georgia, United States

Patients applied

0 patients applied

Trial Officials

Jason Yu, MD

Principal Investigator

Emory University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials